Catalog No.
DHA29104
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-lambda
Applications
Research Grade Biosimilar
Target
TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
O14763
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
PRO95780, anti-DR5, rhuMAb DR5, CAS: 912628-39-8
Note
For research use only. Not suitable for clinical or therapeutic use.
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response, PMID: 21385927
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs), PMID: 25503127
Development of a bioassay as a measure of drozitumab-mediated apoptosis induced by soluble Fc gamma receptors, PMID: 28506821
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl, PMID: 26759246
Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis, PMID: 25880091
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5, PMID: 27330806
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer, PMID: 23061802
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab, PMID: 20179215
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma, PMID: 31842413
Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy, PMID: 23670273
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma, PMID: 28799237
Death receptors as targets in cancer, PMID: 23638798
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells, PMID: 21251615
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway, PMID: 24639349
TRAIL-based therapeutic approaches for the treatment of pediatric malignancies, PMID: 23458616
H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance, PMID: 26136424
Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels, PMID: 27409341
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis, PMID: 27037412
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection, PMID: 23771513
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors, PMID: 24101228
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance, PMID: 23885325
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies, PMID: 20145186
For research use only. Not for human or drug use.
